Compounds > n-carbomethoxycarbonyl-prolyl-phenylalanyl-benzyl ester
Page last updated: 2024-12-07

n-carbomethoxycarbonyl-prolyl-phenylalanyl-benzyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-carbomethoxycarbonyl-prolyl-phenylalanyl-benzyl ester: CPF sticks to the gp120 molecules on the surface of HIV and blocks the site that enables the virus to stick to and penetrate healthy T cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122104
MeSH IDM0185419

Synonyms (14)

Synonym
cpf(ll)
129987-97-9
l-phenylalanine, 1-(methoxyoxoacetyl)-l-prolyl-, phenylmethyl ester
benzyl (2s)-2-[[(2s)-1-(2-methoxy-2-oxo-acetyl)pyrrolidine-2-carbonyl]amino]-3-phenyl-propanoate
n-carbomethoxycarbonyl-l-prolyl-l-phenylalanine benzyl ester
cpf ester
benzyl (2s)-2-[[(2s)-1-(2-methoxy-2-oxoacetyl)pyrrolidine-2-carbonyl]amino]-3-phenylpropanoate
n-carbomethoxycarbonyl-pro-phe-benzyl ester
n-carbomethoxycarbonyl-prolyl-phenylalanyl-benzyl ester
l-phenylalanine, n-(1-(methoxyoxoacetyl)-l-prolyl)-, phenylmethyl ester
DTXSID80156276
carbomethoxycarbonyl-pro-phe-obzl
(s)-benzyl 2-((s)-1-(2-methoxy-2-oxoacetyl)pyrrolidine-2-carboxamido)-3-phenylpropanoate
benzyl (2s)-2-{[(2s)-1-(2-methoxy-2-oxoacetyl)pyrrolidin-2-yl]formamido}-3-phenylpropanoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		01.9810
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		01.9810
Acquired Immune Deficiency Syndrome
[description not available]		01.9710
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		01.9710